<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820612</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00022847</org_study_id>
    <nct_id>NCT00820612</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients</brief_title>
  <official_title>A Prospective, Randomized, Controlled Trial of Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic
      retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of
      disorders of the pancreas and bile duct.

      Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered
      rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to
      definitively determine whether rectally administered indomethacin (a non-steroidal
      antiinflammatory drug)is effective at preventing pancreatitis after ERCP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, randomized, placebo-controlled, double-blinded clinical trial
      of rectal indomethacin in the prevention of post-ERCP pancreatitis in high risk patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped by DSMB for overwhelming benefit of indomethacin (unethical to withhold indomethacin
    from patients)
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-ERCP Pancreatitis</measure>
    <time_frame>5 days</time_frame>
    <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, pancreatic enzyme elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization of at least two nights.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Post-ERCP Pancreatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>100 mg PR once at the time of ERCP</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo suppositories</intervention_name>
    <description>2 placebo suppositories at the time of ERCP</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Included patients are those undergoing ERCP and have one of the following:

          1. Clinical suspicion of sphincter of Oddi dysfunction

          2. History of post-ERCP pancreatitis (at least one episode)

          3. Pancreatic sphincterotomy

          4. Pre-cut (access) sphincterotomy

          5. &gt; 8 cannulation attempts

          6. Pneumatic dilation of intact biliary sphincter

          7. Ampullectomy

        or at least 2 of the following:

          1. Age &lt; 50 years old &amp; female gender

          2. History of recurrent pancreatitis (at least 2 episodes)

          3. â‰¥3 pancreatic injections, with at least one injection to tail

          4. Pancreatic acinarization

          5. Pancreatic brush cytology

        Exclusion Criteria:

          1. Unwillingness or inability to consent for the study

          2. Age &lt; 18 years

          3. Intrauterine pregnancy

          4. Breast feeding mother

          5. Standard contraindications to ERCP

          6. Allergy to Aspirin or NSAIDs

          7. Renal failure (Cr &gt; 1.4)

          8. Active or recent (within 4 weeks) gastrointestinal hemorrhage

          9. Acute pancreatitis (lipase peak) within 72 hours

         10. Known chronic calcific pancreatitis

         11. Pancreatic head malignancy

         12. Procedure performed on major papilla/ventral panc duct in pt with pancreas divisum (no
             manipulation of minor papilla)

         13. ERCP for biliary stent removal or exchange without anticipated pancreatogram

         14. Subjects with prior biliary sphincterotomy now scheduled for repeat biliary therapy
             without anticipated pancreatogram

         15. Anticipated inability to follow protocol

         16. Endoscopist discretion: low risk (&lt;10%) of post-ERCP pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Badih J Elmunzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <results_first_submitted>January 10, 2013</results_first_submitted>
  <results_first_submitted_qc>January 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2013</results_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Badih Joseph Elmunzer</investigator_full_name>
    <investigator_title>Assistant Professor, Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between February 2009 and July 2011, 602 subjects were enrolled at 4 university-affiliated medical centers in the United States.</recruitment_details>
      <pre_assignment_details>Of the 799 consented subjects, 169 were not randomized because an inclusion criterion was not met, 11 were not randomized because an exclusion criterion was met, and 17 were not randomized because ERCP not performed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>2 placebo suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
        </group>
        <group group_id="P2">
          <title>Indomethacin</title>
          <description>2 50-mg indomethacin suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>2 placebo suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
        </group>
        <group group_id="B2">
          <title>Indomethacin</title>
          <description>2 50-mg indomethacin suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="307"/>
            <count group_id="B2" value="295"/>
            <count group_id="B3" value="602"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="13.1"/>
                    <measurement group_id="B2" value="44.5" spread="13.5"/>
                    <measurement group_id="B3" value="45.3" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-ERCP Pancreatitis</title>
        <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, pancreatic enzyme elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization of at least two nights.</description>
        <time_frame>5 days</time_frame>
        <population>100% completed follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 placebo suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin</title>
            <description>2 50-mg indomethacin suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-ERCP Pancreatitis</title>
          <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, pancreatic enzyme elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization of at least two nights.</description>
          <population>100% completed follow-up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="37.6"/>
                    <measurement group_id="O2" value="27" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>All reported adverse events were events potentially related to the study medication. The other major adverse event was post-ERCP pancreatitis, which was reported as the primary outcome, but would not be related to the treatment. All patients were systematically followed for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>2 placebo suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
        </group>
        <group group_id="E2">
          <title>Indomethacin</title>
          <description>2 50-mg indomethacin suppositories. The suppositories were administered immediately after ERCP while the patient was still in the procedure room.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="307"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Post-ercp pancreatitis</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="307"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>B. Joseph Elmunzer, MD.</name_or_title>
      <organization>University of Michigan</organization>
      <phone>735 615 6652</phone>
      <email>badihe@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

